PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: NN9838, AM833
⚖️MetabolicLong-acting amylin analog that activates amylin receptors in the area postrema and hypothalamus to reduce appetite, slow gastric emptying, and suppress post-meal glucagon secretion. Works on a distinct pathway from GLP-1 agonists, making it ideal for combination therapy.
Lau et al. (Lancet): Phase 2 RCT showing cagrilintide 4.5mg weekly achieved 10.8% weight loss vs 3.0% placebo at 26 weeks, with acceptable safety profile.
strongFrias et al. (Lancet): CagriSema combination achieved 15.6% weight loss at 32 weeks in type 2 diabetes patients — superior to either agent alone.
strongReview of amylin's role in energy homeostasis and why dual amylin-calcitonin receptor agonists like cagrilintide represent a new weight loss mechanism distinct from GLP-1.
moderateGenerally well-tolerated in Phase 2 trials. Main side effects are GI-related (nausea, vomiting). Novo Nordisk is developing CagriSema (cagrilintide + semaglutide) as next-gen obesity treatment. Research-only peptide.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
Clinical trial doses: 0.3-4.5mg weekly with dose escalation over 4-8 weeks. Start low (0.3-0.6mg) and increase every 4 weeks to minimize GI side effects.
Week 1
Appetite suppression begins; reduced food cravings
Weeks 2-4
Measurable weight loss (1-2 lbs/week); improved meal portion control
Month 2-3
10-11% body weight loss at clinical doses; improved glycemic markers
Long-term
Clinical trials show sustained weight loss through 26+ weeks; CagriSema in Phase 3 trials
| Side Effect | Incidence | Severity |
|---|---|---|
Nausea Most common during dose escalation; typically resolves in 2-4 weeks | ~25% of users | moderate |
Diarrhea | ~10% of users | mild |
Vomiting | ~8% of users | moderate |
Injection site reaction | ~5% of users | mild |
Constipation | ~8% of users | mild |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Weekly Peptide Research
New studies · vendor alerts · protocol tips
No spam. Unsubscribe anytime. Research use only.